8-99871656-ACAGTG-AAGAA
Variant summary
Our verdict is Pathogenic. Variant got 12 ACMG points: 12P and 0B. PVS1_ModeratePM2PP5_Very_Strong
The NM_152564.5(VPS13B):c.11705_11709delCAGTGinsAGAA(p.Thr3902fs) variant causes a frameshift, missense change involving the alteration of a non-conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. Variant has been reported in ClinVar as Likely pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. TV3902K) has been classified as Pathogenic.
Frequency
Consequence
NM_152564.5 frameshift, missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 12 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
VPS13B | NM_017890.5 | c.11780_11784delCAGTGinsAGAA | p.Thr3927fs | frameshift_variant, missense_variant | 61/62 | ENST00000358544.7 | NP_060360.3 | |
VPS13B | NM_152564.5 | c.11705_11709delCAGTGinsAGAA | p.Thr3902fs | frameshift_variant, missense_variant | 61/62 | ENST00000357162.7 | NP_689777.3 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
VPS13B | ENST00000358544.7 | c.11780_11784delCAGTGinsAGAA | p.Thr3927fs | frameshift_variant, missense_variant | 61/62 | 1 | NM_017890.5 | ENSP00000351346.2 | ||
VPS13B | ENST00000357162.7 | c.11705_11709delCAGTGinsAGAA | p.Thr3902fs | frameshift_variant, missense_variant | 61/62 | 1 | NM_152564.5 | ENSP00000349685.2 |
Frequencies
GnomAD3 genomes Cov.: 33
GnomAD4 genome Cov.: 33
ClinVar
Submissions by phenotype
Cohen syndrome Pathogenic:4
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Dec 31, 2023 | This sequence change creates a premature translational stop signal (p.Thr3927Lysfs*15) in the VPS13B gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 95 amino acid(s) of the VPS13B protein. Information on the frequency of this variant in the gnomAD database is not available, as this variant may be reported differently in the database. This premature translational stop signal has been observed in individuals with Cohen syndrome (PMID: 16648375). This variant is also known as two separate variants in cis (c.11780delC and c.11783TG>AA). This variant disrupts a region of the VPS13B protein in which other variant(s) (p.Asn3954Lysfs*60) have been determined to be pathogenic (PMID: 20656880). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Apr 19, 2024 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Jun 16, 2020 | Variant summary: VPS13B c.11780_11784delinsAGAA (p.Thr3927LysfsX15) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. Truncations downstream of this position have been classified as pathogenic by our laboratory. The variant was absent in 251434 control chromosomes. c.11780_11784delinsAGAA has been reported in the literature in at-least one individual affected with Cohen Syndrome (example, Seifert_2006). To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Two clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All laboratories classified the variant as pathogenic (n=1)/likely pathogenic (n=1). Based on the evidence outlined above, the variant was classified as pathogenic. - |
Likely pathogenic, criteria provided, single submitter | literature only | Counsyl | Feb 13, 2015 | - - |
Inborn genetic diseases Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Jan 15, 2020 | The alteration results in a premature stop codon: _x000D_ _x000D_ The c.11780_11784delCAGTGinsAGAA (p.T3927Kfs*15) alteration, located in exon 61 (coding exon 60) of the VPS13B gene, results from the deletion of 5 nucleotides and insertion of 4 nucleotides at positions 11780 to 11784, causing a translational frameshift with a predicted alternate stop codon after 15 amino acids. Frameshifts are typically deleterious in nature; however, this frameshift occurs at the 3' terminus of VPS13B, is not expected to trigger nonsense-mediated mRNA decay, and a truncated mutant protein could still be expressed (Maquat, 2004). This alteration impacts the last 82 amino acids of the protein and the exact functional impact of these altered amino acids is unknown at this time; however, other frameshift alterations downstream of this alteration have been reported in the in individuals with a phenotype consistent with Cohen syndrome (Kolehmainen, 2004; El Chehadeh, 2010). The alteration is rare in population databases:_x000D_ _x000D_ Based on data from the Genome Aggregation Database (gnomAD), the VPS13B c.11780_11784delCAGTGinsAGAA (p.T3927Kfs*15) alteration was observed in 0.0004% (1/251434) of total alleles studied. The alteration has been observed in affected individuals: _x000D_ _x000D_ This alteration was reported in a patient with suspected Cohen syndrome, whose phenotype included microcephaly, developmental delay, typical facial features, myopia, narrow hands/feet, and neutropenia, and who was heterozygous for a second frameshift alteration (Seifert, 2006). Based on the available evidence, this alteration is classified as likely pathogenic. - |
VPS13B-related disorder Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Jul 02, 2024 | The VPS13B c.11705_11709delinsAGAA variant is predicted to result in a frameshift and premature protein termination (p.Thr3902Lysfs*15). This variant has been reported in the compound heterozygous state in an individual with Cohen syndrome (Seifert et al., 2006. PubMed ID: 16648375). This variant has not been reported in a large population database (http://gnomad.broadinstitute.org), indicating this variant is rare. Frameshift variants in VPS13B are expected to be pathogenic. This variant is interpreted as pathogenic. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at